IMM — ImmuPharma Share News
0.000.00%
Last trade - 00:00New peer-reviewed publication
P140 International Patent Filing Update
Half-year Financial Report
Holding(s) in Company
Bioanalytical CRO partner for Kapiglucagon
Brief: Immupharma Selects Thermo Fisher Scientific As Drug Product CDMO For Kapiglucagon Program
Thermo Fisher CDMO selected for Kapiglucagon pro
University of Murcia research relating to P140
Incanthera plc – Corporate Update & Board Changes
Notice of AGM & Annual Report & Accounts
Brief: Immupharma Reports Loss Of £1.8 Million For Year Ended Dec 31, 2025
Final Results
Brief: Immupharma Initiates IND-Enabling Program For Kapiglucagon To Treat Diabetes
Holding(s) in Company
Chairman’s Open Letter to Shareholders
P140 Program Update
Result of WRAP Retail Offer and TVR
‘Investor Meet Company’ presentation on 20 March
WRAP Retail Offer for up to £1.5 million